BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD)

CO2 GRO Inc. announces that the Board of Directors has approved the grant of 1,680,000 stock options to participants of the Company’s stock option plan.

RaySearch Laboratories AB announces that a sales agent agreement has been signed with Canon Medical Systems USA, Inc., enabling RaySearch America’s salesforce to promote Canon Medical’s Aquilion Large Bore CT and Celesteion PET/CT products.

Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of premature birth and a major contributor to adverse maternal outcomes and maternal death.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company’s recombinant protein vaccine candidate against COVID-19.

Inspira Pharmaceuticals Limited (Inspira or the Company), a biotechnology company developing novel bioactive molecules based on proprietary plant extracts to treat respiratory infections, today announced the appointment of Dr Jessica Jackson as an Non-Executive Director.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia.

Metavention, Inc. announces the initiation of the MODUS Study (ACTRN12620000412932), to treat patients with both type 2 diabetes and hypertension using a catheter-based, minimally invasive approach.

Pennsylvania Dermatology Partners announced that they’ve completed a rebrand initiative which includes a new logo and company name, Dermatology Partners.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present 4 posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021.